1. Home
  2. PAYS vs CABA Comparison

PAYS vs CABA Comparison

Compare PAYS & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysign Inc.

PAYS

Paysign Inc.

HOLD

Current Price

$6.04

Market Cap

293.4M

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.22

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAYS
CABA
Founded
2001
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
293.4M
319.6M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
PAYS
CABA
Price
$6.04
$3.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$9.42
$14.50
AVG Volume (30 Days)
788.5K
4.3M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
85.71
10.26
EPS
0.09
N/A
Revenue
$24,120,434.00
N/A
Revenue This Year
$33.83
N/A
Revenue Next Year
$14.89
N/A
P/E Ratio
$65.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.08
$1.26
52 Week High
$8.88
$4.23

Technical Indicators

Market Signals
Indicator
PAYS
CABA
Relative Strength Index (RSI) 49.77 46.13
Support Level $5.09 $2.17
Resistance Level $7.05 $3.54
Average True Range (ATR) 0.48 0.34
MACD -0.15 -0.05
Stochastic Oscillator 55.26 33.33

Price Performance

Historical Comparison
PAYS
CABA

About PAYS Paysign Inc.

PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: